Alessandra Daigneault Biography and Net Worth

General Counsel of NRx Pharmaceuticals


Mrs. Daigneault joined NRx as its Corporate Secretary in September 2020. Prior to joining NRx, she was co-founder and Chief Operating Officer of Quantum Governance LLC, where she continues to serve as a director. She also served as Vice President and Chief Legal Counsel for Teligent, Inc. and its successor companies, First Avenue Networks and FiberTower Corporation, all publicly traded telecommunications companies, from October 2000 to May 2008. Ms. Daigneault began her legal career with Milbank LLP and was a Partner at the Washington, D.C. law firm of Tucker, Flyer & Lewis (now Venable LLP) where she represented clients on various corporate and commercial transactions. Ms. Daigneault holds a Bachelor of Science, Magna Cum Laude, from Georgetown University and a Juris Doctor from Georgetown University Law Center.

How do I contact Alessandra Daigneault?

The corporate mailing address for Ms. Daigneault and other NRx Pharmaceuticals executives is 2645 N. Federal Highway Suite 230, Delray Beach FL, 33483. NRx Pharmaceuticals can also be reached via phone at (484) 254-6134 and via email at [email protected]. Learn More on Alessandra Daigneault's contact information.

Has Alessandra Daigneault been buying or selling shares of NRx Pharmaceuticals?

Alessandra Daigneault has not been actively trading shares of NRx Pharmaceuticals in the last ninety days. Most recently, Alessandra Daigneault sold 33,715 shares of the business's stock in a transaction on Monday, August 23rd. The shares were sold at an average price of $13.11, for a transaction totalling $442,003.65. Learn More on Alessandra Daigneault's trading history.

Who are NRx Pharmaceuticals' active insiders?

NRx Pharmaceuticals' insider roster includes Robert Besthof (Insider), and Alessandra Daigneault (General Counsel). Learn More on NRx Pharmaceuticals' active insiders.

Are insiders buying or selling shares of NRx Pharmaceuticals?

In the last year, NRx Pharmaceuticals insiders bought shares 2 times. They purchased a total of 235,000 shares worth more than $75,200.00. The most recent insider tranaction occured on August, 30th when Director Aaron Gorovitz bought 35,000 shares worth more than $11,200.00. Insiders at NRx Pharmaceuticals own 21.1% of the company. Learn More about insider trades at NRx Pharmaceuticals.

Information on this page was last updated on 8/30/2023.

Alessandra Daigneault Insider Trading History at NRx Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/23/2021Sell33,715$13.11$442,003.65View SEC Filing Icon  
See Full Table

Alessandra Daigneault Buying and Selling Activity at NRx Pharmaceuticals

This chart shows Alessandra Daigneault's buying and selling at NRx Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

NRx Pharmaceuticals Company Overview

NRx Pharmaceuticals logo
NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics based on N-methyl-D-aspartate platform for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned FDA-designated investigational breakthrough therapy for suicidal treatment-resistant bipolar depression and chronic pain; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of acute suicidality in depression. The company has a partnership with Alvogen and Lotus to develop and commercialize NRX-101 for the suicidal bipolar depression treatment, as well as an agreement with Nephron Pharmaceuticals, Inc. to develop ketamine. The company was founded in 2015 and is based in Wilmington, Delaware.
Read More

Today's Range

Now: $0.49
Low: $0.45
High: $0.54

50 Day Range

MA: $0.46
Low: $0.29
High: $0.70

2 Week Range

Now: $0.49
Low: $0.22
High: $1.20

Volume

990,257 shs

Average Volume

1,490,605 shs

Market Capitalization

$45.31 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.99